

TABLE OF CONTENTS

	Page
ACKNOWLEDGEMENT	iii
ABSTRACT	iv
TABLE OF CONTENTS	viii
LIST OF TABLES	xii
LIST OF ILLUSTRATIONS	xiii
ABBREVIATIONS	xix
CHAPTER I: INTRODUCTION	
I. INTRODUCTION	1
Molecular Genetic and Cellular Expression of Alkaline Phosphatase Isoenzymes	1
Structures of the Alkaline Phosphatase Isoenzymes	2
Post-translational Modification of Alkaline Phosphatase Isoenzymes	5
The Isoforms of Intestinal Alkaline phosphatase Isoenzyme	7
Physiological Rule of Intestinal Alkaline Phosphatase	9
Factors Affecting the Appearance of Intestinal Alkaline Phosphatase Isoenzyme in Serum	9
Intestinal Alkaline Phosphatase in Serum of Normal and Diseases	10
Separation of Alkaline Phosphatase Isoenzyme from Tissues	13
Determination of Intestinal Alkaline Phosphatase Isoenzymes by Electrophoretic Method	13

	Page
Method for Determination of Total ALP Activity in Serum Affected the Intestinal Alkaline Phosphatase Activity Fractions	14
Advantageousness of Determination of Intestinal Alkaline Phosphatase Activity and Intestinal Alkaline Phosphatase Isoforms in Normal Serum	14
II. LITERATURE REVIEW	16
ABH Secretor Status	16
Metabolic Differences between Secretors and Non-secretors	16
Relationship of Serum IAP Isoenzyme with ABO Blood Group and Secretor status	17
Food Intake Affected the Increase of IAP activity in Serum in Relation to Blood Group and Secretor status	20
Disease Susceptibility among Secretors and Non-secretors	21
Serum Intestinal Alkaline Phosphatase and Blood Group Associated Diseases	23
III. OBJECTIVES	28
CHAPTER II: MATERIALS AND METHODS	
A. Materials	29
1. Specimens	29
2. Instruments	29
3. Chemical and Reagents	30
4. Other Materials	31
B. Methods	32
I. Method for Determination of ABO Blood Group and Secretor Status	
1. Determination of ABO Blood Grouping	32
2. Determination of ABH secretion	32

	Page
II. Preparation of ALP Isoenzyme from Tissues for Use as Electrophoresis Control ALP isoenzymes	34
III. Screening of Patient Conditions to Rule out Liver Disease	34
IV. Method for Determination of Total Alkaline Phosphatase Activity	35
1. Measurement of Total ALP Activity by a Kinetic Method Using Double-Beam UV 2450 Spectrophotometer	35
2. Quality Control of Total ALP Activity Determination	36
V. Method for Separation of ALP Isoenzyme by Polyacrylamide Gel Electrophoresis (PAGE)	37
VI. Method for Identification of ALP isoenzymes by Using Biochemical Characterization of the IAP Isoform Molecule on PAGE Containing Triton X-100	38
VII. Method Use to Confirm the Presence of IAP Isoforms in Serum and Molecular Weight Determination: Western blot analysis	39
VIII. Determination of IAP Isoform Activity and Ratios	43
IX. Statistic Analysis	43
 CHAPTER III: RESULTS	
I. Blood Group Typing and ABH Secretor Status of Subjects	44
II. Screening of Liver Disease on Subjects by Determination of the Liver Enzymes in Serum Specimens	45
1. Analytical precision of method for liver enzyme determination	45
2. AST and ALT activities in serum specimens	46
III. Total ALP Activity in Serum of Subjects in Relation to Blood Group and Secretor Status	47
1. Analytical precision of total ALP activity determination	47
2. Total ALP activity measured in normal serum	49

	Page
IV. Separation and Identification of ALP Isoenzymes in Tissue Extract and Serum Specimens by 6% Polyacrylamide Gel Electrophoresis (PAGE) Containing Triton X-100	55
1. Identification of types of ALP isoenzymes by neuraminidase treatment on PAGE	55
2. Analytical precision of IAP isoform separation on PAGE	58
3. Separation and identification of IAP isoforms in serum of secretors & non-secretors by PAGE	59
4. IAP & TNAP activities in sera of secretors & non-secretors calculated from separated bands on PAGE	62
V. Molecular Mass Determination and Confirmation of the Presence of the IAP Isoforms in Normal Sera by Western Blot Analysis	71
CHAPTER IV	
I. DISCUSSION	81
II. CONCLUSION	90
REFERENCES	91
APPENDICES	100
APPENDIX A: Reagent Preparations	101
APPENDIX B: Protocols for ABO Blood Grouping and ABH Secretion Determination	107
APPENDIX C: Scanning of ALP isoenzyme bands and Images processing by Scion Image Program	111
APPENDIX D: Application of Mean Reference Value for Monitoring of Intestinal Diseases	118
CURRICULUM VITAE	132

LIST OF TABLES

Table	Page
1. The ABO blood group and ABH secretion status of the subjects	45
2. Analytical precision of AST and ALT determination	46
3. AST and ALT activities in normal serum of all blood groups with no regard to ABH secretion status	46
4. Analytical precision of total ALP activity (U/L) determination in Shimudzu UV 2450 Spectrophotometer	48
5. Total ALP activity (U/L) in different blood groups with secretor status	51
6. The relation of total ALP activity (U/L) in serum of B or O secretors and B or O non- secretors with the ages of subjects	54
7. The precision of IAP isoforms separated by PAGE	59
8. The summary of IAP isoenzyme activities in serum of B or O secretors and B or O non-secretors as separated by PAGE	63
9. The ALP isoenzyme activities in serum of B or O secretors and non-secretors at various ranges of ages separated by PAGE	64
10. The summary of ALP isoenzyme activities in normal sera of different blood groups with regard to secretor status and separated by PAGE method	70
11. The fractions of IAP isoenzyme in normal sera of B or O secretors and non-secretors	80
12. Summary of the fractions of IAP isoenzyme detected in normal serum by the Western blot analysis	80
13. The fractions of IAP isoenzyme in normal serum of secretors, normal serum of Non-secretors and serum of patients	121

LIST OF ILLUSTRATIONS

Figure	Page
<p>1. Models of association of dimeric GPI-anchored alkaline phosphatase with the bilayer surface. The structure of ALP (PLAP represented model) is shown in dimer. (A) The N-terminal α-helix and loop (residues 1-24) are pointed by arrows and the GPI anchor covalently linked to the C-terminus of each monomer is shown. The model of the crystal structure of the ALP dimer showing the two GPI anchors in a fully extended conformation ("lollipop model") with the protein moiety some distance from the membrane. (B) The protein portion may "flop down" onto the membrane causing it to be in direct contact with the bilayer surface, with the GPI anchor folded up underneath the protein.</p>	3
<p>2. Protein secretory pathway as a model of targeting of ALP isoenzymes anchoring to the lipid bilayer membrane (or secreting the other proteins out of the cells as vacuol). The Gogi apparatus is highly specialized for a variety of functions, including protein glycosylation and subsequent transport of glycoprotein (e.g. ALP to their destination).</p>	6
<p>3. The distribution of ALP activity values in Level I control serum determined in Shimudzu UV 2450 Spectrophotometer</p>	48
<p>4. The distribution of ALP activity values in Level II control serum determined in Shimudzu UV 2450 Spectrophotometer</p>	49
<p>5. The total ALP activity (U/L) in serum of B or O secretors and non-secretors. Upper: the distribution of total ALP activity in serum of B or O secretors and non-secretors. Lower: The comparison of the mean and standard deviation of total ALP activity in both group, the different of mean was significant at $p < 0.001$.</p>	52

Figure	Page
6. Total ALP activity (U/L) in serum of B or O secretors and non-secretors compared with the other blood group. Upper : the distribution of total ALP activity in serum of B or O secretors and non-secretors compared with the other blood groups and lower: the comparison of the mean and standard deviation of total ALP activity of both group with the other blood group , the different of mean was significant at $p < 0.001$.	53
7. Polyacrylamide gel electrophoresis demonstrated ALP isoenzymes migration with and without neuraminidase treatment. Lane 1, 2: IAP isoenzyme, Lane 3, 4: PLAP isoenzyme, Lane 5, 6: Liver& bone isoenzymes, Lane 7, 8: LAP isoenzyme and Lane 9, 10: liver disease serum. C and T represent control and neuraminidase treatment respectively.	56
8. ALP isoenzyme scanning patterns before and after treating with neuraminidase. (Band scanning using Scion image program) [A], [B], [C] and [D] were calf colon tissue extract (500 U/L), human placental extract (1,200 U/L), liver-bone control [Helena Laboratories, USA.] and bovine liver extract (250 U/L), respectively.	57
9. Separation of IAP isoforms on 6% PAGE containing Triton X-100. (IAP tissues extract from calf colon tissue, activity of 500 U/L)	58
10. The distributions of activities of different isoforms of IAP isoenzyme extracted from calf colon tissue and separated by PAGE. Upper,middle and lower figures were NIAP, HIAP1 and HIAP2 isoforms, respectively.	60
11. The migration of ALP isoenzymes in serum of secretor & non-secretor on 6% PAGE containing Triton X-100, before & after neuraminidase treatment. Lane 1, 2: IAP isoenzyme control (Calf colon tissue), Lane 3, 4 and Lane 5, 6: sera of B or O secretors. Lane 7, 8 and Lane 9, 10: sera of B or O non-secretors. C and T represent control and neuraminidase treatment.	61


Figure	Page
12. Comparison of TIAP activity (U/L) in sera of B or O secretors and non-secretors ($p < 0.0001$). Upper: The distribution of the analytical values and lower: the mean and standard deviation of TIAP activities	65
13. Comparison of NIAP activity (U/L) in sera of B or O secretors and non-secretors, $p < 0.0001$. Upper: The distribution of the analytical values and lower: the mean and standard deviation of NIAP activities.	66
14. Comparison of TNAP activity (U/L) in sera of B or O secretors and non-secretors (NS). Upper: The distribution of the analytical values and lower: the mean and standard deviation of TNAP activities.	67
15. The ALP isoenzymes in normal serum of other blood group (A, AB) compared with B or O separated by PAGE method.	69
16. Molecular masses of three IAP isoforms in serum of B or O secretors and non-secretors on Western blot analysis. Lane 1: Molecular mass markers, Lane 2: LAP control, Lane 3: IAP control, Lane 4-6 normal serum of B or O secretors and Lane 7-9 normal serum of B or O non-secretors.	72
17. The ALP isoenzymes in serum of B or O secretors and non-secretors on SDS-PAGE. Lane 1: Molecular mass markers, Lane 2: LAP control, Lane 3: IAP control, Lane 4-6 serum of B or O secretors and Lane 7-9 serum of B or O non-secretors.	72
18. Molecular weight determination of IAP isoforms as compared with molecular weight marker (Full range Rainbow, Amersham, USA.)	73
19. The comparison of IAP isoform separation detected in serum of B or O secretors and non- secretors by Western blot analysis.	75

Figure	Page
20. The intensity (density) of NIAP fraction in sera of B or O secretors and non- secretors. Upper: The distribution in fractions of NIAP Lower: The comparison of mean \pm SD of NIAP fraction in sera of both groups of secretor status.	76
21. The intensity (density) of HIAP fractions in sera of B or O secretors and non-secretors. Upper: The distribution in fractions of HIAP and Lower: The comparison of mean \pm SD of HIAP fractions in sera of both groups of secretor status.	77
22. The intensity (density) of HIAP/NIAP ratios in sera of B or O secretors and non-secretors. Upper: The distribution in fractions of HIAP/NIAP ratios Lower: The comparison of mean \pm SD of HIAP/NIAP ratios in sera of both groups of secretor status	78
23. Total ALP activity of patients' sera as compared with the reference value determined in this study. Upper: The distribution of total ALP activity in normal serum of B or O blood group and patients' sera. Lower: The comparison of the mean and standard deviation of total ALP activity in both groups, * the difference of mean was significant at $p < 0.01$.	120
24. Total ALP activity of patients' sera as compared with the reference value determined in this study. Upper: The distribution of total ALP activity in normal serum of B or O secretors, B or O non-secretors and patient sera. Lower: The comparison of the mean and standard deviation of total ALP activity in different groups, * the difference of mean was significant at $p < 0.01$.	121
25. The ALP isoenzymes in patients' sera separated by PAGE method. Lane 1, 2: IAP standard control (C-neu untreated) and C-neu treated, Lane 3-10: patients' serum untreated and C-neu treated, respectively.	123

Figure	Page
26. TIAP activity of patients' sera as compared with the reference value determined in this study (PAGE method). Upper: The distribution of TIAP activity in normal serum of B or O secretors, B or O non-secretors and patient sera. Lower: The comparison of the mean and standard deviation of TIAP activity in different groups.	124
27. NIAP activity of patients' sera as compared with the reference value determined in this study (PAGE method). Upper: The distribution of NIAP activity in normal serum of B or O secretors, B or O non-secretors and patient sera. Lower: The comparison of the mean and standard deviation of NIAP activity in different groups.	125
28. TNAP activity of patients' sera as compared with the reference value determined in this study (PAGE method). Upper: The distribution of TNAP activity in normal serum of B or O secretors, B or O non-secretors and patient sera. Lower: The comparison of the means and standard deviations of TNAP activity in different group.	126
29. Molecular masses of three IAP isoforms in sera of B or O secretors, non-secretors and patient sera by Western blot analysis. Lane 1&2 normal serum of B or O secretors, Lane 3&4 serum of patients with intestinal disease and Lane 5&6 normal serum of B or O non-secretors.	127
30. The intensity of NIAP fractions in patients' sera as compared with the mean reference value determined in this study. Upper: The distribution of intensity of NIAP fraction in normal serum of B or O secretors, B or O non-secretors and patient sera. Lower: The comparison of the means and standard deviations of intensity of NIAP fractions in different groups.	129
31. The intensity of HIAP fractions in patients' sera as compared with the mean reference value determined in this study. Upper: The distribution of intensity of HIAP fraction in normal serum of B or O secretors, B or O non-secretors and patient sera. Lower: The comparison of the means and standard deviations of intensity of HIAP fractions in different groups.	130

Figure**Page**

32. The intensity of HIAP/NIAP ratios of patients' sera as compared with the 131 mean reference value determined in this study. Upper: The distribution of intensity of HIAP/NIAP ratios in normal serum of B or O secretors, B or O non-secretors and patient sera. Lower: The comparison of the means and standard deviations of intensity of HIAP/NIAP ratios in different groups.



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright © by Chiang Mai University
All rights reserved